Все публикации

1:28:47

Race Oncology (ASX:RAC) 2024 Annual General Meeting

0:04:59

Interview with Dr Ron Hargreaves - 'The Early Development of Bisantrene'

0:10:59

Interview with Dr Ving Lee - 'The Early Development of Bisantrene'

0:33:20

Sharewise Webinar with Race Oncology CEO Daniel Tillett

0:08:11

Race CEO Daniel Tillett Joins Hot Copper webinar to discuss bringing medical developments to market

0:08:36

Introducing Dr Rodney Cusack

0:11:37

Dr Susan Dent on cardio-oncology

1:31:25

Race Oncology ASX RAC 2023 Annual General Meeting

1:31:49

Race Oncology Investor Briefing

0:39:10

Triangle Insights presents insights from their commercial assessment of Zantrene

0:08:22

Race Oncology starts world-first cancer trial to treat rare form of leukaemia

0:24:28

MST Access Late Stage Development Biotech Forum

1:13:30

Race Oncology AGM Nov 2022

0:01:56

Race Oncology featured on NBN news

0:00:36

Race trials new Zantrene drug for Extramedullary Acute Myeloid Leukaemia (EMD AML) – Animation

0:54:22

Race Oncology (ASX:RAC) Investor Briefing - Melbourne 20th Oct 2022

0:45:09

Race Oncology June 2022 Quarterly Investor Briefing

0:15:14

Race Oncology at Gold Coast Investor Showcase 2022

0:44:09

Race online Q+A investor briefing - recorded 8 December 2021

0:38:32

Investor Presentation

0:03:28

Race Oncology Share Purchase Plan Explained

0:05:17

Race Oncology AGM 2021 Share Purchase Plan Explained

0:28:01

Race Oncology AGM 2021 CEO & CSO presentation with Share Purchase Program

0:06:42

Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®